{"links":{"feed":"https://www.erudio.com/reports/omaha-004-nct06136650/feed.json","html":"https://www.erudio.com/reports/omaha-004-nct06136650","json":"https://www.erudio.com/reports/omaha-004-nct06136650.json","markdown":"https://www.erudio.com/reports/omaha-004-nct06136650.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"omaha-004-nct06136650"}},"request":"https://www.erudio.com/contact?report=omaha-004-nct06136650"},"offer":{"cited_clinicians":2,"cited_commentary_sources":7,"verified_hcp_statements":61,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":3},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=omaha-004-nct06136650","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=omaha-004-nct06136650","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/omaha-004-nct06136650","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 61 verified statements · 10 from 2 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-14T12:51:07.624599Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":0},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":3,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":3,"title":"Secondary endpoints"},{"claim_count":16,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":4,"title":"Safety and tolerability"},{"claim_count":11,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":19,"coverage":"discussed","id":"A1","source_count":7,"title":"Resistance biology and upstream steroid blockade in mCRPC"},{"claim_count":11,"coverage":"discussed","id":"A2","source_count":3,"title":"Mutation-guided selection and ctDNA interpretation"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":1,"title":"Recruitment, access and anticipated treatment role"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":11,"cited_clinicians":2,"cited_clinicians_by_role":{"physician, Medical oncology":1,"physician, Urology":1},"cited_physicians":2,"cited_sources":9,"claims_by_expression_type":{"comparison":3,"experience":1,"interpretation":21,"opinion":6,"primary_context":8,"question":4,"restatement":15,"uncertainty":1,"unspecified":2},"claims_by_kind":{"protocol_statement":6,"publication_statement":5,"source_observation":50},"clinician_statements":10,"evidence_units":43,"findings":5,"organisational_accounts":1,"people_cited":3,"people_identity_verified":3,"people_total":3,"screened_sources":20,"verified_claims":61},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":8},"limitations":3,"links":{"context":4,"support":12},"ma_question":true,"named_voices":0,"passages":12,"sources":3,"sources_by_kind":{"media":2,"publication":1}},"title":"One video calls OMAHA-004 mutation-specific; another presentation describes testing both mutation groups"},{"cited_clinicians":1,"id":"F2","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":4,"views":4},"limitations":3,"links":{"context":3,"support":10},"ma_question":true,"named_voices":2,"passages":8,"sources":5,"sources_by_kind":{"commentary":1,"media":3,"publication":1}},"title":"Two named contributors stress steroid replacement; one video asks about major side effects"},{"cited_clinicians":2,"id":"F3","structure":{"claims":19,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":8,"views":8},"limitations":3,"links":{"context":1,"support":21},"ma_question":true,"named_voices":3,"passages":13,"sources":7,"sources_by_kind":{"commentary":4,"media":3}},"title":"Two named contributors see upstream steroid blockade as a strategy for hormonal resistance"},{"cited_clinicians":2,"id":"F4","structure":{"claims":17,"claims_by_group":{"comparisons":2,"experience":0,"questions":0,"restated":13,"views":2},"limitations":4,"links":{"context":1,"support":26},"ma_question":true,"named_voices":2,"passages":11,"sources":7,"sources_by_kind":{"commentary":3,"media":2,"publication":1,"registry":1}},"title":"One X account frames OMAHA-004 as earlier testing against ARPI switching"},{"cited_clinicians":0,"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":1,"questions":1,"restated":3,"views":3},"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":1,"passages":4,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"One LinkedIn account presents recruitment as access and anticipates another treatment option"}],"open_question":{"basis":"From findings F1 (11 statements in 3 sources) and F4 (17 statements from 2 speakers in 7 sources)","cited_claim_ids":["claim-8f8c0d1dd9e01a97b98e","claim-8e77745f2059a2f778e3","claim-7ffbb09d060093f3bd88","claim-ca8f858b4ef9d0fec939","claim-d8592757eb56f7cb8f2b","claim-9f51ab354df47607da5a","claim-00bfb8769551112ba310","claim-fc09fc70a3790a698df1","claim-1dc07cb5703006687ada","claim-c6a05256e98212a39152","claim-247723bb742fe45c7c62","claim-a44eeb66f0d11a73a036","claim-b54befd07c68392ace2d","claim-4dfe65e574d5828ca9cd","claim-8ac253f5e3520cc5e374","claim-5f841d4eca2da572f43a","claim-67928a4086a52b707d28","claim-20a011db44aa6c1e0f51","claim-cb0cc2b7536a24119f5d","claim-f21163244721f6219a6b"],"finding_ids":["F1","F4"],"question":"What do clinicians say OMAHA-004 needs to show on radiographic progression-free and overall survival before considering opevesostat instead of ARPI switching in AR-LBD mutation-negative as well as mutation-positive mCRPC after one ARPI without prior mCRPC taxane?"},"sections":{"analysis":[{"id":"section-1","level":3,"title":"One video calls OMAHA-004 mutation-specific; another presentation describes testing both mutation groups"},{"id":"section-2","level":3,"title":"Two named contributors stress steroid replacement; one video asks about major side effects"},{"id":"section-3","level":3,"title":"Two named contributors see upstream steroid blockade as a strategy for hormonal resistance"},{"id":"section-4","level":3,"title":"One X account frames OMAHA-004 as earlier testing against ARPI switching"},{"id":"section-5","level":3,"title":"One LinkedIn account presents recruitment as access and anticipates another treatment option"},{"id":"section-6","level":3,"title":"Beyond the trial population"},{"id":"section-7","level":4,"title":"One video calls earlier data “staggering”; a LinkedIn account calls CYPIDES activity a “major success”"},{"id":"section-8","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":3}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":3}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":8},{"id":"F4","shared_claims":5},{"id":"F5","shared_claims":4}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F4","shared_claims":6}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":8}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F4","shared_claims":9},{"id":"F5","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-14T12:51:07.624599Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-14T13:05:17Z","record_hash":"7920fd25b649ae36ff5c76590def3850324a3dabb42df8518d57f3f14b4f0bb0","release_hash":"964256a45296bdaf9a0012c39cbe94b1d0b58ef67a7050f27793c8b8aa8cdfc6","report_id":"erudio-nct06136650","run_id":"cf1dbd6d-04db-425f-ab2a-04244ea7b3e1","schema_version":"5.0","slug":"omaha-004-nct06136650","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"In one discussion, a speaker hopes OMAHA-004 could become standard care for AR-LBD-mutated disease because of earlier subgroup activity, not demonstrated trial benefit. In separate discussion, a speaker describes earlier activity without AR mutations, leaving mutation status unproven as a selection rule for opevesostat. A medical oncologist described in the sources as involved in the trial stresses that broad steroid suppression requires hormone replacement. The sources reviewed for this edition provide no comparative benefit or safety outcomes.","examples":[],"meta_description":"20 sources screened · 61 verified statements (10 from clinicians verified by NPI or staff page) from 9 sources · 5 findings. Updated Nov 14, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-14T13:05:17Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":20},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","52 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 18 sources about other trials or topics are not included.","The sources reviewed describe selected public discussion, not a representative sample of HCP opinion or treatment practice.","Discussion that does not use the trial identifier or recognized trial names may be missing.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","No OMAHA-004 comparative efficacy or safety outcomes are provided. Earlier-study response figures, mechanistic assertions and future treatment expectations must remain separate from phase 3 findings.","The registry and publication describe different endpoint hierarchies. The registry records the OS amendment sequence, but the descriptions should not be collapsed into one undated account.","Earlier-study populations, response definitions and mutation-prevalence estimates are not sufficiently aligned to support direct numerical comparisons.","The video names an earlier study C-Beta; other sources name CYPIDES. Their identity should not be assumed from similar subject matter.","Recruitment and access statements describe what was reported at the time, not current site availability or access outside research."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":1,"registry":1,"regulatory":0,"x_thread":3,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":7,"methods":2},"count":9,"evidence_window":{"end":"2026-10-23","start":"2025-04-30"},"retrieval_snapshot":"2026-11-14T12:09:59.029877Z","timeline":[{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W04"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W43"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06136650:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06136650:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:41732008","quote_policy":"no_derivatives"},{"id":"openfda:69a2388c-94e6-4039-9b9a-224507edfa47:20261106","quote_policy":"short_quote_link_out"},{"id":"openfda:933e28ef-05e8-419e-a786-21eab67f33a2:20260624","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7323289995190943746","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2f249c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1743240848299458635:750d6a5c-be3e-4158-8805-5364dfa3e3ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1763692318853587214:3bf98773-841f-4a52-9550-f045d5df5c29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797268987614535687:b4381b80-092a-46c6-b536-c6c3e12df3f0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797274472468078896:57f56c19-1253-49a7-896e-067a3bbdd744","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797319845404410150:1c2bb607-4999-42f4-80fd-f2264d13ee59","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1825171175187616242:f1655e27-b3b8-4b60-bc38-614536fee4dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864698975544090856:14800e5e-3633-408f-a354-7ec3db5bcd23","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1864769302659768539:d4a8f2d4-8796-4168-a510-11eecfe12d02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991495413720109405:48d52d2e-86a9-4674-a80f-e463b7713226","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027488462538936430:6aa37b57-e323-4818-9828-7fbc79318fb5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027791144554234348:357ff14c-6572-41a2-bc47-8e16ffe7d92a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2050511552919257494:927fde40-f73e-4169-8408-570031e2c124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056172008535191908:43396377-52e5-4336-ba99-9e8c6941ab0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061136867441950870:216e575b-4e70-4e54-b010-d9ee103679e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061254891083862265:8c6a4d42-28d2-4a0c-bef2-24eaaa958e0f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118726050947735915:c529abe6-771b-41de-a80b-3efe6a7477b2","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:37GsSPejkT8","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:DbeYMuV_tdo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":20},"count":20,"evidence_window":{"end":"2026-11-06","start":"2024-01-05"},"retrieval_snapshot":"2026-11-14T12:09:59.029877Z","timeline":[{"count":1,"week":"2024-W01"},{"count":1,"week":"2024-W09"},{"count":3,"week":"2024-W22"},{"count":1,"week":"2024-W33"},{"count":2,"week":"2024-W49"},{"count":1,"week":"2025-W18"},{"count":1,"week":"2025-W20"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W43"},{"count":1,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":9,"other":0,"podcast":4,"publication":10,"registry":1,"regulatory":0,"x_thread":9,"x_video":0,"youtube":28}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":[{"label":"2026 ASCO Annual Meeting","slug":"asco26","sources":2}],"drugs":[{"reason":"Unmapped registry intervention: opevesostat","status":"unmapped"},{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"reason":"Unmapped registry intervention: fludrocortisone acetate","status":"unmapped"},{"reason":"Unmapped registry intervention: hydrocortisone","status":"unmapped"},{"brand_names":["Zytiga"],"label":"abiraterone acetate","slug":"abiraterone-acetate"},{"brand_names":["Cortan","Delta-Dome","Deltasone","Fernisone","Liquid Pred","Meticorten","Orasone","Paracort","Prednicen-M","Rayos","Servisone"],"label":"prednisone","slug":"prednisone"},{"brand_names":["Xtandi"],"label":"enzalutamide","slug":"enzalutamide"}],"indications":[{"reason":"Unmapped registry condition: Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"OMAHA-004","aliases":["OMAHA-004","MK-5684-004","A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)"],"brief_title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Prostatic Neoplasms"],"display_condition":"metastatic castration-resistant prostate cancer post one NHA","display_interventions":[["opevesostat"]],"enrollment":{"count":1314,"type":"ESTIMATED"},"interventions":[{"name":"Opevesostat","synonyms":["MK-5684"],"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Fludrocortisone acetate","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Hydrocortisone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Abiraterone acetate","synonyms":["Zytiga","Yonsa"],"type":"DRUG"},{"name":"Prednisone acetate","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Enzalutamide","synonyms":["Xtandi"],"type":"DRUG"}],"nct_id":"NCT06136650","official_title":"MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-05-10","type":"ESTIMATED"},"primary_endpoints":[{"description":"OS is defined as the time from randomization to death due to any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to approximately 82 months"}],"registered_date":{"date":"2023-11-18","type":"ACTUAL"},"registry_last_updated":"2026-10-20","registry_url":"https://clinicaltrials.gov/study/NCT06136650","short_name":"OMAHA-004","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2023-12-18","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"5684-004","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-5684-004","type":"other"},{"domain":"Japan Registry of Clinical Trial (jRCT)","id":"jRCT2031240030","type":"registry"},{"domain":"EU CT","id":"2023-504957-11-00","type":"registry"},{"domain":"UTN","id":"U1111-1288-5002","type":"registry"}],"study_type":"INTERVENTIONAL"}}}